News & Updates
Filter by Specialty:
5-day antibiotic use viable in CAP patients with clinical stability
Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.
5-day antibiotic use viable in CAP patients with clinical stability
16 May 2025
Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19
Updated data from the EPIC-HR* trial show reduced duration of COVID-19 symptoms and utilization of healthcare resources with nirmatrelvir/ritonavir (NMV/r) in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19.
Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19
16 May 2025
Life quality poorer in COVID-19 survivors with ongoing symptoms
In adults who have survived the COVID-19 pandemic, health-related quality of life (HRQoL) is high among those who had either recovered from post-COVID-19 condition (PCC) or had never been afflicted with PCC, according to a study.
Life quality poorer in COVID-19 survivors with ongoing symptoms
13 May 2025
Monoclonal antibodies vs COVID-19 up risks of hepatotoxicity, neutropenia
Treatment with monoclonal antibodies (mAbs) among COVID-19 patients is associated with a higher risk of hepatotoxicity and neutropenia when compared with standard of care (SoC) or placebo, reports a study.
